Acute lymphoblastic leukemia (ALL), B-cell lymphoma, and adult-onset ALL are among the malignancies for which CD19 is the principal target, and CAR-T cells have demonstrated encouraging treatment outcomes for hematologic malignancies. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.